-
Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action
Wednesday, October 6, 2021 - 7:17am | 269Read More...Surrozen Inc (NASDAQ: SRZN) announced that preclinical data from its inflammatory bowel disease (IBD) program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related: See Why Surrozen Stock Is Surging On Tuesday. Preclinical data of SZN-1326...
-
AzurRx BioPharma To Acquire First Wave Bio For $229M
Monday, September 13, 2021 - 9:19am | 307Read More...AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small...
-
Takeda To Lead Finch-Partnered Microbiome IBD Drug
Tuesday, August 10, 2021 - 3:54pm | 220Read More...Finch Therapeutics Group Inc (NASDAQ: FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE: TAK) has elected to take the lead on the development of FIN-524, now known as TAK-524, in ulcerative colitis. When Takeda teamed up with Finch Therapeutics in 2017 on inflammatory...
-
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Thursday, June 17, 2021 - 10:26am | 162Read More...Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic medicine for inflammatory bowel disease (IBD). Under the terms of the agreement, Synlogic and Roche will collaborate to...
-
Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002
Monday, March 29, 2021 - 8:33am | 236Read More...Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-002 for all indications, including severe pediatric-onset...
-
Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies
Thursday, March 4, 2021 - 9:12am | 272Read More...Galapagos NV (NASDAQ: GLPG) has announced interim results from two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel disease (MANTA study) or rheumatic conditions (MANTA-RAy study). Out of the 248...
